INTERVIEW – President of Unicancer, Fr.r Jean-Yves Blay explains to the Figaro why this approach, long reserved for the most seriously affected patients, is increasingly being used in the front line.
Since the 2010s, immunotherapy has been revolutionizing cancer treatment practices. Initially reserved for a minority of patients in the advanced stages of the disease, this approach, which consists of mobilizing the patient’s immune system so that it recognizes and destroys cancer cells, is increasingly becoming an essential pillar of modern oncology. More targeted, potentially more effective and often less toxic than conventional treatments (chemotherapy, radiotherapy, surgery), immunotherapy should become one of the first-line treatments for a wide range of cancers in the years to come. As the 2024 edition of the European Society for Medical Oncology (ESMO) congress has just closed, the Pr Jean-Yves Blay, president of Unicancer, looks back at the paradigm shift that is taking shape as scientific data accumulates.
LE FIGARO. – What are we talking about when we…
This article is reserved for subscribers. You have 85% left to discover.
Flash Sale
€1.99 per month for 6 months. No commitment.
Already subscribed? Log in
